Wall Street brokerages expect Zafgen Inc (NASDAQ:ZFGN) to report earnings per share of ($0.45) for the current quarter, according to Zacks. Zero analysts have made estimates for Zafgen’s earnings. The highest EPS estimate is ($0.43) and the lowest is ($0.46). Zafgen posted earnings of ($0.46) per share in the same quarter last year, which would indicate a positive year-over-year growth rate of 2.2%. The business is expected to announce its next earnings report on Tuesday, November 6th.
On average, analysts expect that Zafgen will report full year earnings of ($2.05) per share for the current fiscal year, with EPS estimates ranging from ($2.09) to ($1.99). For the next year, analysts expect that the firm will report earnings of ($1.95) per share, with EPS estimates ranging from ($2.22) to ($1.81). Zacks’ earnings per share calculations are a mean average based on a survey of research analysts that follow Zafgen.
Zafgen (NASDAQ:ZFGN) last released its quarterly earnings data on Tuesday, August 7th. The biopharmaceutical company reported ($0.57) EPS for the quarter, beating the consensus estimate of ($0.59) by $0.02.
Several analysts have recently weighed in on ZFGN shares. BidaskClub upgraded Zafgen from a “hold” rating to a “buy” rating in a research note on Tuesday, July 3rd. ValuEngine upgraded Zafgen from a “hold” rating to a “buy” rating in a research note on Tuesday, June 26th. Cowen restated a “hold” rating on shares of Zafgen in a research note on Monday, June 25th. Zacks Investment Research upgraded Zafgen from a “sell” rating to a “hold” rating in a research note on Monday, July 16th. Finally, Wedbush started coverage on Zafgen in a research note on Thursday, August 2nd. They set an “outperform” rating and a $14.00 target price for the company. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $15.25.
In other news, insider Thomas E. Hughes sold 32,000 shares of the firm’s stock in a transaction dated Thursday, June 28th. The stock was sold at an average price of $10.00, for a total transaction of $320,000.00. Following the completion of the sale, the insider now directly owns 125,247 shares in the company, valued at $1,252,470. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 23.70% of the stock is owned by company insiders.
Large investors have recently bought and sold shares of the stock. Voya Investment Management LLC acquired a new position in Zafgen in the second quarter worth about $104,000. Los Angeles Capital Management & Equity Research Inc. acquired a new position in Zafgen in the second quarter worth about $110,000. Trexquant Investment LP bought a new position in Zafgen in the second quarter worth about $117,000. Private Advisor Group LLC bought a new position in Zafgen in the second quarter worth about $153,000. Finally, Barclays PLC lifted its holdings in Zafgen by 139,086.7% in the first quarter. Barclays PLC now owns 20,878 shares of the biopharmaceutical company’s stock worth $155,000 after acquiring an additional 20,863 shares during the last quarter. Institutional investors and hedge funds own 72.58% of the company’s stock.
NASDAQ:ZFGN traded down $0.20 during mid-day trading on Wednesday, hitting $9.92. The company had a trading volume of 3,009 shares, compared to its average volume of 226,715. The company has a debt-to-equity ratio of 0.36, a current ratio of 8.42 and a quick ratio of 8.42. Zafgen has a 1 year low of $3.24 and a 1 year high of $11.36. The firm has a market capitalization of $384.61 million, a PE ratio of -5.22 and a beta of -0.62.
Zafgen, Inc, a clinical-stage biopharmaceutical company, develops therapies for patients suffering from metabolic diseases comprising type 2 diabetes, Prader-Willi syndrome (PWS), and other metabolically related disorders. The company's lead product candidate is ZGN-1061, a fumagillin-class methionine aminopeptidase 2 (MetAP2) inhibitor administered by subcutaneous injection, which is in Phase 2 clinical trial and profiled for its utility in the treatment of type 2 diabetes and other related metabolic disorders.
Read More: What is Compound Annual Growth Rate (CAGR)?
Get a free copy of the Zacks research report on Zafgen (ZFGN)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Zafgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zafgen and related companies with MarketBeat.com's FREE daily email newsletter.